Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 2
1952 2
1953 1
1960 1
1973 2
1978 1
1982 1
1985 2
1990 2
1991 2
1992 7
1993 3
1994 3
1995 3
1996 5
1997 4
1998 3
1999 5
2000 6
2001 9
2002 7
2003 12
2004 7
2005 9
2006 10
2007 11
2008 8
2009 12
2010 3
2011 18
2012 8
2013 8
2014 9
2015 6
2016 20
2017 14
2018 8
2019 8
2020 8
2021 7
2022 12
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

256 results

Results by year

Filters applied: . Clear all
Page 1
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, Drapek LC, Ly L, Baglini CV, Blaszkowsky LS, Ferrone CR, Parikh AR, Weekes CD, Nipp RD, Kwak EL, Allen JN, Corcoran RB, Ting DT, Faris JE, Zhu AX, Goyal L, Berger DL, Qadan M, Lillemoe KD, Talele N, Jain RK, DeLaney TF, Duda DG, Boucher Y, Fernández-Del Castillo C, Hong TS. Murphy JE, et al. Among authors: boucher y. JAMA Oncol. 2019 Jul 1;5(7):1020-1027. doi: 10.1001/jamaoncol.2019.0892. JAMA Oncol. 2019. PMID: 31145418 Free PMC article. Clinical Trial.
Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic Cancer.
Boucher Y, Posada JM, Subudhi S, Kumar AS, Rosario SR, Gu L, Kumra H, Mino-Kenudson M, Talele NP, Duda DG, Fukumura D, Wo JY, Clark JW, Ryan DP, Fernandez-Del Castillo C, Hong TS, Pittet MJ, Jain RK. Boucher Y, et al. Clin Cancer Res. 2023 Apr 14;29(8):1605-1619. doi: 10.1158/1078-0432.CCR-22-1630. Clin Cancer Res. 2023. PMID: 36749873 Free PMC article. Clinical Trial.
Advancing pathogen genomics in resource-limited settings.
Pronyk PM, de Alwis R, Rockett R, Basile K, Boucher YF, Pang V, Sessions O, Getchell M, Golubchik T, Lam C, Lin R, Mak TM, Marais B, Twee-Hee Ong R, Clapham HE, Wang L, Cahyorini Y, Polotan FGM, Rukminiati Y, Sim E, Suster C, Smith GJD, Sintchenko V. Pronyk PM, et al. Among authors: boucher yf. Cell Genom. 2023 Nov 17;3(12):100443. doi: 10.1016/j.xgen.2023.100443. eCollection 2023 Dec 13. Cell Genom. 2023. PMID: 38116115 Free PMC article. Review.
[Specificities of orofacial neuropathic pain].
Moreau N, Peirs C, Dallel R, Boucher Y. Moreau N, et al. Among authors: boucher y. Med Sci (Paris). 2024 Jan;40(1):64-71. doi: 10.1051/medsci/2023197. Epub 2024 Feb 1. Med Sci (Paris). 2024. PMID: 38299905 French.
Is burning mouth syndrome associated with stress? A meta-analysis.
Porporatti AL, Schroder ÂGD, Lebel A, Moreau N, Misery L, Alajbeg I, Braud A, Boucher Y. Porporatti AL, et al. Among authors: boucher y. J Oral Rehabil. 2023 Nov;50(11):1279-1315. doi: 10.1111/joor.13536. Epub 2023 Jul 4. J Oral Rehabil. 2023. PMID: 37332081 Review.
Taste disorder's management: a systematic review.
Braud A, Boucher Y. Braud A, et al. Among authors: boucher y. Clin Oral Investig. 2020 Jun;24(6):1889-1908. doi: 10.1007/s00784-020-03299-0. Epub 2020 May 8. Clin Oral Investig. 2020. PMID: 32385655
Refuting phylogenetic relationships.
Bucknam J, Boucher Y, Bapteste E. Bucknam J, et al. Among authors: boucher y. Biol Direct. 2006 Sep 6;1:26. doi: 10.1186/1745-6150-1-26. Biol Direct. 2006. PMID: 16956399 Free PMC article.
256 results